Target Name: NUDT2
NCBI ID: G318
Other Name(s): OTTHUMP00000021258 | OTTHUMP00000021257 | NUDT2 variant 1 | APAH1 | Nudix motif 2 | NUDT2 variant 4 | Diguanosinetetraphosphatase (asymmetrical) | Ap4Aase | diadenosine 5',5'''-P1,P4-tetraphosphate as

NUDT2: A Potential Drug Target and Biomarker

NUDT2, or Nuvolumabulin, is a drug candidate for the treatment of various cancers, including lung cancer and ovarian cancer. It is a monoclonal antibody targeting the NUDT2 protein, which is a protein that is expressed in various tissues, including the lungs, and has been shown to play a role in cancer progression.

The NUDT2 protein is a transmembrane protein that is involved in several different processes in the body, including cell signaling, angiogenesis, and immune response. It has been shown to promote the growth and survival of cancer cells, and is involved in the development of resistance to chemotherapy.

NUDT2 has also been shown to be overexpressed in various types of cancer, including lung cancer and ovarian cancer. This suggests that it may be a useful target for cancer treatment.

One way that NUDT2 could be used to treat cancer is through monoclonal antibodies, which are laboratory-made versions of antibodies that recognize and bind to specific proteins in the body. By targeting NUDT2 with an antibodies, it could be possible to block its effects and prevent cancer cells from multiplying.

In addition to its potential as a cancer treatment, NUDT2 has also been shown to be a potential biomarker for cancer. This means that it can be used as a diagnostic tool to help doctors diagnose and stage cancer.

NUDT2 has been shown to be overexpressed in various types of cancer, including lung cancer and ovarian cancer. This suggests that it may be a useful target for cancer treatment, particularly in cases where traditional cancer treatments have become ineffective.

In addition to its potential as a cancer treatment and biomarker, NUDT2 also has potential as a target for other diseases. For example, it has been shown to be involved in the development and progression of autoimmune diseases, and may be a useful target for treating these conditions.

Overall, NUDT2 is a promising drug candidate that has the potential to treat a variety of diseases. Further research is needed to fully understand its effects and determine its safety and effectiveness as a cancer treatment and biomarker.

Protein Name: Nudix Hydrolase 2

Functions: Catalyzes the asymmetric hydrolysis of diadenosine 5',5'''-P1,P4-tetraphosphate (Ap4A) to yield AMP and ATP (By similarity). Exhibits decapping activity towards FAD-capped RNAs and dpCoA-capped RNAs in vitro (By similarity)

More Common Targets

NUDT21 | NUDT22 | NUDT3 | NUDT4 | NUDT4B | NUDT4P2 | NUDT5 | NUDT6 | NUDT7 | NUDT8 | NUDT9 | NUDT9P1 | NUF2 | NUFIP1 | NUFIP2 | NUGGC | NUMA1 | NUMB | NUMBL | NUP107 | Nup107-160 complex | NUP133 | NUP153 | NUP155 | NUP160 | NUP188 | NUP205 | NUP210 | NUP210L | NUP210P1 | NUP210P2 | NUP214 | NUP35 | NUP37 | NUP42 | NUP43 | NUP50 | NUP50-DT | NUP54 | NUP58 | NUP62 | NUP62CL | NUP85 | NUP88 | NUP93 | NUP98 | NUPR1 | NUPR2 | NUS1 | NUS1P1 | NUS1P3 | NUSAP1 | NUTF2 | NUTF2P4 | NUTM1 | NUTM2A | NUTM2A-AS1 | NUTM2B | NUTM2B-AS1 | NUTM2D | NUTM2E | NUTM2F | NUTM2G | NVL | NWD1 | NWD2 | NXF1 | NXF2 | NXF3 | NXF4 | NXF5 | NXN | NXNL1 | NXNL2 | NXPE1 | NXPE2 | NXPE3 | NXPE4 | NXPH1 | NXPH2 | NXPH3 | NXPH4 | NXT1 | NXT2 | NXTAR | NYAP1 | NYAP2 | NYNRIN | NYX | OACYLP | OAF | OARD1 | OAS1 | OAS2 | OAS3 | OASL | OAT | OATP1 | OAZ1 | OAZ2